Skip to main content
Peter MacCallum Cancer Centre
  • Donate
  • Location
  • Search
  • English
  • Easy English
  • العَرَبِيَّة Arabic
  • 中文 Chinese
  • Eλληνικά Greek
  • हिन्दी Hindi
  • Italiano Italian
  • Tagalog Tagalog
  • Türkçe Turkish
  • Tiếng Việt Vietnamese
  • About
  • Profiles
  • Careers
  • Education
  • News
  • Events
  • Get involved
  • Contact
  • Cancer types
    • Breast
    • Upper Gastrointestinal
    • Lower Gastrointestinal
    • Genitourinary Oncology
    • Gynae-oncology
    • Clinical Haematology
    • Head & neck
    • Lung
    • Melanoma & Skin
    • Neuro-oncology
    • Paediatric
    • Sarcoma
    • Cancer of unknown primary
  • Our services
    • Diagnosis & investigations
    • Treatment
    • Support services
    • Cancer information & resources
  • Coming to Peter Mac
    • Melbourne
    • Bendigo
    • Box Hill
    • Moorabbin
    • Sunshine
    • Telehealth
  • Research & discovery
    • Clinical research
    • Research laboratories
    • CoE Cellular Immunotherapy
    • Core facilities
    • ProsTIC
    • Research cohort studies
    • Research programs
    • Doing research with us
    • Commercialisation, partnerships and industry engagement
    • Publications
    • Research strategy
    • Education in research
    • Biomedical Animation
    • National Particle Therapy Symposium
    • Use your cancer experience to help guide research
  • Clinical Trial Care
    • Patients and Families
    • Health Professionals
    • Clinical Trial Sponsors
  1. Home
  2. Profiles
  3. Prof Michael Hofman
Director of Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC); Nuclear Medicine and Molecular Imaging Physician

Prof Michael Hofman

Nuclear Medicine

Biography

Professor Michael Hofman is a nuclear medicine physician and physician-scientist at the Peter MacCallum Cancer Centre in Melbourne. He previously completed a research fellowship at Guy's & St Thomas' in London. He has broad research interest in radiopharmaceuticals for imaging and therapy (Theranostics) in Oncology. This includes neuroendocrine tumours and haematologic applications and more recently has focussed on improving outcomes for men with prostate cancer.

Dr Hofman has a strong track record leading Phase I, II and III clinical trials ranging from first-in-human evaluation of novel radiopharmaceuticals to conducting large multi-centre randomised clinical trials. In the latter, through his involvement on the scientific committee of the The Australasian Radiopharmaceutical Trials Network (ArtNet), he has established a network of more than 10 centres around Australia with multi-disciplinary expertise culminated in research presented at leading conferences (ESMO, ASCO, EAU) and published in high impact journal such as The Lancet. He has active grants as chief investigator totalling more than $15 million dollars including the Prostate Cancer Foundation (PCF), Movember, Medical Research Future Fund (MRFF), Prostate Cancer Foundation of Australia (PCFA) and the U.S. Department of Defence.

Prof Hofman has a leading academic track record for his specialty relative to experience, with over 170 peer reviewed manuscripts and book chapters. He has received a number of international awards including the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Image of the Year 2018 and awards for best scientific research at several international conferences. He is a frequent invited speaker at national and international meetings, and was the co-chair of the scientific committee for the 4th World Theranostic World Congress in 2016. In 2015 he was elected a fellow of the International Cancer Imaging Society, one of three Australians recognized by the society. He was a member of the oncology subcommittee of the ongoing MBS Review where he advocates for fair and equitable access to PET scanning for patients with cancer.

Prof Hofman is a keen educator, and was the RACP representative on the RACP / RANZCR Joint Specialty Advisory Committee  (JSAC) in Nuclear Medicine from 2008-2015 . In this capacity, he was the co-author of the national Nuclear Medicine Advanced Training Curriculum. He has been the director of training for molecular imaging at Peter MacCallum, and has been supervisor of several post-graduate researchers.

In 2016, Prof Hofman undertook a six month sabbatical in leading centres in Germany, Israel, France and the United Kingdom focusing on PET/MRI, preclinical PET translational research, novel radiotracers and theranostics.

He currently serves as the vice chair of the oncology program for the SNMMI, the peak body representing nuclear medicine and molecular imaging professionals. He is an associate editor for several journals including the international editorial committee of the Journal of Nuclear Medicine and the nuclear medicine subsection editor for Cancer Imaging.  Prof  Hofman is a member of the PMCC Research Leadership Group and is the Program Director of the newly established Prostate Theranostics and Imaging Centre of Excellence (ProsTIC).

IN THE NEWS

A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy  - proPSMA study

Nuclear medicine could be a game changer for advanced prostate cancer, Australian Financial Review

ASCO 2020 oral presentation: TheraP Trial  Study results

Related Links

Genitourinary Oncology 

Nuclear Medicine

Positron Emission Tomography Pet

Awards

2018: SNMMI Image of the Year

2016: Cum Laude Award at RSNA for best Molecular Imaging Educational Exhibit

2015: Fellow of the International Cancer Imaging Society (ICIS)

2015: ANSTO Award, Australian and New Zealand Society of Nuclear Medicine for significant innovation in research or clinical practice in the field of Nuclear Medicine

2014: Henry Wagner Award 2014 for best oral scientific presentation at the World Federation in Nuclear Medicine and Biology World Federation in Nuclear Medicine and Biology scientific meeting

2013: Roentogen Society of North America (RSNA) Cum Laude Award 2013 for the top 5% ranked educational exhibits

2011: ANSTO Award, Australian and New Zealand Society of Nuclear Medicine

2011: Eckert & Ziegler Abstract Award for top 5 ranking scientific abtracts at the European Association of Nuclear Medicine scentific meeting, Birmingham

2011: Jan Esser Science Award for the Best Oral Presentation, World Federation in Nuclear Medicine and Biology, Cape Town

Qualifications

MBBS (Hons), FRACP, FAANMS, FICIS

Director of Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC); Nuclear Medicine and Molecular Imaging Physician

Prof Michael Hofman

Nuclear Medicine

Peter MacCallum Cancer Centre

  • Victorian Comprehensive Cancer Centre building
    305 Grattan Street
    Melbourne VIC 3000
    Australia
    Peter MacCallum Cancer Centre
  • (03) 8559 5000 (In an emergency, call 000)
  • (03) 8559 7379 (Main fax)
  • (03) 8559 7371 (Referrals fax)
  • Locations
    • Melbourne
    • Bendigo
    • Box Hill
    • Moorabbin
    • Sunshine
  • About us
    • Get involved
    • Upcoming events
    • Partnerships
    • Patient charter
  • Cancer types
  • Cancer services
    • Diagnosis & investigations
    • Treatments
    • Cancer info & resources
  • Refer your patient
  • Peter MacCallum Cancer Foundation
  • Australian Cancer Survivorship Centre
  • Research & discovery
    • Clinical research & trials
    • Research cohort studies
    • Research labs
  • Careers
  • Education

Our Community

  • Facebook
  • Twitter
  • Instagram
  • YouTube
  • LinkedIn
  • Contact us
Comments & feedback

The Peter MacCallum Cancer Centre acknowledges the traditional owners of the land on which our five sites are located throughout Victoria. We recognise their strength and resilience and pay our respects to their Elders past and present.

Languages
Auslan
Interpreter
Site by Icon Agency
  • Privacy policy
  • Terms & Conditions
  • Intranet